NervGen reported expanded CONNECT SCI results showing durable functional improvements in chronic spinal cord injury patients treated with NVG‑291; improvements continued through week 16 and persisted in blinded exit interviews up to one year. The company also presented physiological evidence—reductions in hyperactive reticulospinal signaling and increased corticospinal signaling—supporting a mechanistic basis for recovery. NervGen completed a Type C meeting with FDA, which confirmed multiple regulatory pathways to support approval. The data set and FDA feedback set the stage for next steps in regulatory engagement and potential registrational planning for a therapy that would be first‑in‑class for neurologic repair.